X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
MYLAN
Dec-14
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9304,142-   
Low Rs5172,919-   
Sales per share (Unadj.) Rs322.61,417.8-  
Earnings per share (Unadj.) Rs28.5170.8-  
Cash flow per share (Unadj.) Rs39.2274.9-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0704.8-  
Shares outstanding (eoy) m282.17378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.22.5 90.1%   
Avg P/E ratio x25.420.7 122.9%  
P/CF ratio (eoy) x18.512.8 143.8%  
Price / Book Value ratio x4.05.0 79.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2061,335,681 15.3%   
No. of employees `00013.725.0 54.9%   
Total wages/salary Rs m18,7180-   
Avg. sales/employee Rs Th6,636.821,458.5 30.9%   
Avg. wages/employee Rs Th1,364.70-   
Avg. net profit/employee Rs Th586.12,585.0 22.7%   
INCOME DATA
Net Sales Rs m91,031536,463 17.0%  
Other income Rs m914-3,127 -29.2%   
Total revenues Rs m91,945533,336 17.2%   
Gross profit Rs m16,154133,421 12.1%  
Depreciation Rs m3,01939,401 7.7%   
Interest Rs m2,85623,140 12.3%   
Profit before tax Rs m11,19367,753 16.5%   
Minority Interest Rs m0-278 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1552,849 110.7%   
Profit after tax Rs m8,03964,626 12.4%  
Gross profit margin %17.724.9 71.4%  
Effective tax rate %28.24.2 670.2%   
Net profit margin %8.812.0 73.3%  
BALANCE SHEET DATA
Current assets Rs m69,887471,622 14.8%   
Current liabilities Rs m32,879368,714 8.9%   
Net working cap to sales %40.719.2 211.9%  
Current ratio x2.11.3 166.2%  
Inventory Days Days8178 104.3%  
Debtors Days Days93107 87.2%  
Net fixed assets Rs m28,892124,109 23.3%   
Share capital Rs m28218,971 1.5%   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,635266,675 19.4%   
Long term debt Rs m41,418398,386 10.4%   
Total assets Rs m125,9541,074,142 11.7%  
Interest coverage x4.93.9 125.2%   
Debt to equity ratio x0.81.5 53.7%  
Sales to assets ratio x0.70.5 144.7%   
Return on assets %8.68.2 105.9%  
Return on equity %15.624.2 64.2%  
Return on capital %15.113.6 110.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,48170,518 23.4%  
From Investments Rs m-10,133-55,613 18.2%  
From Financial Activity Rs m-4,685-18,582 25.2%  
Net Cashflow Rs m1,770-3,676 -48.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 69.49 Rs / USD

Compare GLENMARK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: AUROBINDO PHARMA  VENUS REMEDIES  DR. REDDYS LAB  DR. DATSONS LABS  DISHMAN PHARMA  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

My Top 7 Stocks to Buy as Modi Returns to Power(The 5 Minute Wrapup)

May 23, 2019

The Modi government is all set to come back to power. With a stable government at the centre, how should you play the stock market?

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS